PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer

Sarah P. Blagden(Churchill Hospital), Essam Ghazaly(Queen Mary University of London), Laura Spiers(Churchill Hospital), David J. Harrison(NHS Lothian), Shibani Nicum(London Cancer), Chathunissa Gnanaranjan(Queen Mary University of London), Ajithkumar Sukumaran(Imperial College London), Astrid Lipplaa(Churchill Hospital), Victoria K. Woodcock(Churchill Hospital)

Annals of Oncology

September 1, 2017

10.1093/annonc/mdx372.039

Cited by 2

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

|Annals of Oncology|2024|277

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222